Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gastric Cancer

  Free Subscription

Articles published in
J Clin Oncol
    March 2024
  1. SALANI F, Vivaldi C, Rreka E, Genovesi V, et al
    Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Carcinomatosis: The Need for Clear Answers Through Proper Questions.
    J Clin Oncol. 2024 Mar 14:JCO2302611. doi: 10.1200/JCO.23.02611.
    >> Share

    February 2024
  2. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    >> Share

  3. GALLANIS AF, Gamble LA, Samaranayake SG, Lopez R, et al
    Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.
    J Clin Oncol. 2024;42:421-430.
    >> Share

    December 2023
  4. MOEHLER M, Xiao H, Blum SI, Elimova E, et al
    Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
    J Clin Oncol. 2023;41:5388-5399.
    >> Share

    November 2023
  5. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    >> Share

  6. DEL RIVERO J, Perez K, Kennedy EB, Mittra ES, et al
    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    J Clin Oncol. 2023;41:5049-5067.
    >> Share

    October 2023
  7. RAU B, Lang H, Koenigsrainer A, Gockel I, et al
    Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
    J Clin Oncol. 2023 Oct 31:JCO2202867. doi: 10.1200/JCO.22.02867.
    >> Share

  8. LEE CK, Kim HS, Jung M, Kim H, et al
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
    J Clin Oncol. 2023 Oct 26:JCO2300971. doi: 10.1200/JCO.23.00971.
    >> Share

    September 2023
  9. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    >> Share

    March 2023
  10. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    >> Share

    February 2023
  11. YAMAGUCHI K, Bang YJ, Iwasa S, Sugimoto N, et al
    Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
    J Clin Oncol. 2023;41:816-825.
    >> Share

    January 2023
  12. ANDRE T, Tougeron D, Piessen G, de la Fouchardiere C, et al
    Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    J Clin Oncol. 2023;41:255-265.
    >> Share

    November 2022
  13. HOFHEINZ RD, Merx K, Haag GM, Springfeld C, et al
    FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
    J Clin Oncol. 2022;40:3750-3761.
    >> Share

    August 2022
  14. MARON SB, Moya S, Morano F, Emmett MJ, et al
    Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    J Clin Oncol. 2022;40:2458-2467.
    >> Share

    July 2022
  15. PATEL MA, Kratz JD, Lubner SJ, Loconte NK, et al
    Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102500. doi: 10.1200/JCO.21.02500.
    >> Share

    June 2022
  16. GWEE YX, Chia DKA, So J, Ceelen W, et al
    Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.
    J Clin Oncol. 2022 Jun 1:JCO2102745. doi: 10.1200/JCO.21.02745.
    >> Share

    March 2022
  17. KIM YW, Min JS, Yoon HM, An JY, et al
    Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial.
    J Clin Oncol. 2022 Mar 24:JCO2102242. doi: 10.1200/JCO.21.02242.
    >> Share

    February 2022
  18. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    >> Share

    September 2021
  19. MO DC, Qin L, Ye LJ
    Neoadjuvant Docetaxel, Oxaliplatin, and S-1 in Resectable Advanced Gastric Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2101528. doi: 10.1200/JCO.21.01528.
    >> Share

  20. KANG YK, Yook JH, Park YK, Lee JS, et al
    PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    J Clin Oncol. 2021;39:2903-2913.
    >> Share

    August 2021
  21. TEH SH, Uong S, Lin TY, Shiraga S, et al
    Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health Care System.
    J Clin Oncol. 2021 Aug 2:JCO2100480. doi: 10.1200/JCO.21.00480.
    >> Share

    March 2021
  22. HAFFNER I, Schierle K, Raimundez E, Geier B, et al
    HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
    J Clin Oncol. 2021 Mar 25:JCO2002761. doi: 10.1200/JCO.20.02761.
    >> Share

  23. VAN DER VEEN A, Brenkman HJF, Seesing MFJ, Haverkamp L, et al
    Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial.
    J Clin Oncol. 2021;39:978-989.
    >> Share

  24. SHAH MA, Bodoky G, Starodub A, Cunningham D, et al
    Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
    J Clin Oncol. 2021;39:990-1000.
    >> Share

    January 2021
  25. LU Z, Fang Y, Liu C, Zhang X, et al
    Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 8:JCO2001254. doi: 10.1200/JCO.20.01254.
    >> Share

    November 2020
  26. MOEHLER M, Dvorkin M, Boku N, Ozguroglu M, et al
    Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
    J Clin Oncol. 2020 Nov 16:JCO2000892. doi: 10.1200/JCO.20.00892.
    >> Share

    July 2020
  27. CATENACCI DVT, Rasco D, Lee J, Rha SY, et al
    Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
    J Clin Oncol. 2020;38:2418-2426.
    >> Share

    June 2020
  28. MAKIYAMA A, Sukawa Y, Kashiwada T, Kawada J, et al
    Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    J Clin Oncol. 2020;38:1919-1927.
    >> Share

    April 2020
  29. FUKUOKA S, Hara H, Takahashi N, Kojima T, et al
    Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    J Clin Oncol. 2020 Apr 28:JCO1903296. doi: 10.1200/JCO.19.03296.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016